Evan David Seigerman
Stock Analyst at BMO Capital
(0)
# 2831
Out of 5,297 analysts
42
Total ratings
31.25%
Success rate
9.78%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MRK Merck & Co | Maintains: Market Perform | 105 96 | 87.58 | 9.61% | 4 | Feb 5, 2025 | |
ABBV AbbVie | Maintains: Outperform | 208 215 | 204.2 | 5.29% | 7 | Feb 3, 2025 | |
REPL Replimune Group | Maintains: Outperform | 18 27 | 8.02 | 236.66% | 3 | Jan 22, 2025 | |
NVO Novo Nordisk | Maintains: Outperform | 156 105 | 67.25 | 56.13% | 5 | Dec 23, 2024 | |
REGN Regeneron Pharmaceut... | Maintains: Outperform | 1300 1190 | 616.82 | 92.93% | 5 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 52 57 | n/a | n/a | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 83 100 | 16.37 | 510.87% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 336 355 | 308.24 | 15.17% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 33 36 | 24.75 | 45.45% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 31 72 | n/a | n/a | 4 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 9 3 | 5.13 | -41.52% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 369 396 | 798.18 | -50.39% | 1 | Sep 6, 2022 |